A new base for three Swiss startups

Raizers has tapped into the unserved real estate crowdfunding market in Italy, allowing its clients access to investments in the county. Proptech and Biotech companies PriceHubble and Biognosys have also opened additional sites in the UK and US, respectively. All three expansions align with the companies' growth strategies.

Real estate developments in Italy lack the of VEFA (Sale in the Future State of Completion) system, which allows the developer to receive the fruits of their sales as the work progresses. Swiss real estate crowdfunding platform Raizers has established itself in the Italian market to help close this gap. The startup offers an investment platform that allows individuals and professionals to lend to real estate developers, starting at 1,000 euros, thus giving access to investment opportunities previously reserved for institutions. The company today has over 255 million euros invested with an average return of 10% on more than 250 operations in France, Switzerland, Belgium and Luxembourg.

Since this summer, Raizers enables its clients to diversify their investments by financing operations in Italy. In order to obtain the European PSFP approval, the platform has already initiated its development outside its borders. After several months of preparation at the legal, administrative and commercial levels, the Raizers teams is already offering two financing operations in Italy. Its first object in Milan was attracted 350 investors in a few minutes.

PriceHubble enters the UK
Zurich-based PriceHubble provides accurate property insights that can be digitally integrated into the customer journey, to transform customer interaction and overall business development. Only six years old and with over 200 employees, PriceHubble has already established itself in nine international markets: Switzerland, France, Germany, Austria, Japan, the Netherlands, Belgium, the Czech Republic and Slovakia and serves over 1,500 B2B clients, including well-known international such as Credit Suisse in Switzerland and BNP and Axa in France. Following this strong growth, the company is now tapping into the UK market. The launch in the UK represents the latest in a series of market entries based on acquisitions and greenfield investments in Europe and Asia. With its extensive market experience, PriceHubble is now focusing on partnering with UK banks, wealth managers, estate agents, mortgage advisers, IFAs and FinTechs. The move also comes at a time when the UK property market, its lending and borrowing, and interest rates, following announcements by the UK's Chancellor of the Exchequer's "mini-budget" announcements.

Biogynosys opens US office in Cambridge
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, has opened an office in Cambridge, Massachusetts, a global hub of pharmaceutical and biotechnology companies. The office opening is part of Biognosys’ ongoing expansion into North America and complements their expanding Business Development and Scientific teams in the United States. The office will offer Biognosys employees in the US a place to work and meet and will facilitate meetings and project collaboration with US-based pharma and biotech companies. The office will also foster collaboration with life science companies and academia.

The company offers a versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.